Periodontal disease associates with higher brain amyloid load in normal elderly
- PMID: 25491073
- PMCID: PMC4399973
- DOI: 10.1016/j.neurobiolaging.2014.10.038
Periodontal disease associates with higher brain amyloid load in normal elderly
Abstract
The accumulation of amyloid-β (Aβ) plaques is a central feature of Alzheimer's disease (AD). First reported in animal models, it remains uncertain if peripheral inflammatory and/or infectious conditions in humans can promote Aβ brain accumulation. Periodontal disease, a common chronic infection, has been previously reported to be associated with AD. Thirty-eight cognitively normal, healthy, and community-residing elderly (mean age, 61 and 68% female) were examined in an Alzheimer's Disease Research Center and a University-Based Dental School. Linear regression models (adjusted for age, apolipoprotein E, and smoking) were used to test the hypothesis that periodontal disease assessed by clinical attachment loss was associated with brain Aβ load using (11)C-Pittsburgh compound B (PIB) positron emission tomography imaging. After adjusting for confounders, clinical attachment loss (≥3 mm), representing a history of periodontal inflammatory/infectious burden, was associated with increased PIB uptake in Aβ vulnerable brain regions (p = 0.002). We show for the first time in humans an association between periodontal disease and brain Aβ load. These data are consistent with the previous animal studies showing that peripheral inflammation/infections are sufficient to produce brain Aβ accumulations.
Keywords: Alzheimer's disease; Brain amyloid; Cognition; Infection; Inflammation; PIB-PET; Periodontal disease.
Copyright © 2015 Elsevier Inc. All rights reserved.
Conflict of interest statement
Conflict of interest: No conflict of interest is reported for A. Kamer, P. Corby, R. Craig, D. Saxena, H. Rusinek, S. Vallabhajosula, S. Williams, R. Linker, S. Svetco and C. Shi. L. Mosconi, W. Tsui, and M. de Leon have a patent on an image analysis technology that was licensed to Abiant Imaging, Inc, by NYU, and have a financial interest in this license agreement, and NYU holds stock options on the company. Y. Li, L. Mosconi and M. de Leon have received compensation for consulting services from Abiant Imaging. Dr L. Glodzic was a Principal Investigator on an Investigator-Initiated project funded by Forest Laboratories, Inc, and received an honorarium for serving as a consultant to Roche Pharma.
Figures
Similar articles
-
Parallel ICA of FDG-PET and PiB-PET in three conditions with underlying Alzheimer's pathology.Neuroimage Clin. 2014 Mar 19;4:508-16. doi: 10.1016/j.nicl.2014.03.005. eCollection 2014. Neuroimage Clin. 2014. PMID: 24818077 Free PMC article.
-
Regional dynamics of amyloid-β deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a voxelwise PiB-PET longitudinal study.Brain. 2012 Jul;135(Pt 7):2126-39. doi: 10.1093/brain/aws125. Epub 2012 May 23. Brain. 2012. PMID: 22628162
-
Region-Specific Association of Subjective Cognitive Decline With Tauopathy Independent of Global β-Amyloid Burden.JAMA Neurol. 2017 Dec 1;74(12):1455-1463. doi: 10.1001/jamaneurol.2017.2216. JAMA Neurol. 2017. PMID: 28973551 Free PMC article.
-
[Amyloid PET in Alzheimer research].Brain Nerve. 2010 Jul;62(7):757-67. Brain Nerve. 2010. PMID: 20675880 Review. Japanese.
-
Positron emission tomography radiopharmaceuticals for imaging brain Beta-amyloid.Semin Nucl Med. 2011 Jul;41(4):283-99. doi: 10.1053/j.semnuclmed.2011.02.005. Semin Nucl Med. 2011. PMID: 21624562 Review.
Cited by
-
Periodontal disease's contribution to Alzheimer's disease progression in Down syndrome.Alzheimers Dement (Amst). 2016 Feb 4;2:49-57. doi: 10.1016/j.dadm.2016.01.001. eCollection 2016. Alzheimers Dement (Amst). 2016. PMID: 27239536 Free PMC article. Review.
-
Mutanolysin-Digested Peptidoglycan of Lactobacillus reuteri Promotes the Inhibition of Porphyromonas gingivalis Lipopolysaccharide-Induced Inflammatory Responses through the Regulation of Signaling Cascades via TLR4 Suppression.Int J Mol Sci. 2023 Dec 19;25(1):42. doi: 10.3390/ijms25010042. Int J Mol Sci. 2023. PMID: 38203215 Free PMC article.
-
Microbial involvement in Alzheimer disease development and progression.Mol Neurodegener. 2020 Jul 24;15(1):42. doi: 10.1186/s13024-020-00378-4. Mol Neurodegener. 2020. PMID: 32709243 Free PMC article. Review.
-
Effects of Tooth Loss and the Apolipoprotein E ɛ4 Allele on Mild Memory Impairment in the Fujiwara-kyo Study of Japan: A Nested Case-Control Study.J Alzheimers Dis. 2017;55(2):575-583. doi: 10.3233/JAD-160638. J Alzheimers Dis. 2017. PMID: 27716671 Free PMC article.
-
Porphyromonas gingivalis-Derived Lipopolysaccharide Promotes Glioma Cell Proliferation and Migration via Activating Akt Signaling Pathways.Cells. 2022 Dec 16;11(24):4088. doi: 10.3390/cells11244088. Cells. 2022. PMID: 36552854 Free PMC article.
References
-
- Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, Cooper NR, Eikelenboom P, Emmerling M, Fiebich BL, Finch CE, Frautschy S, Griffin WS, Hampel H, Hull M, Landreth G, Lue L, Mrak R, Mackenzie IR, McGeer PL, O’Banion MK, Pachter J, Pasinetti G, Plata-Salaman C, Rogers J, Rydel R, Shen Y, Streit W, Strohmeyer R, Tooyoma I, Van Muiswinkel FL, Veerhuis R, Walker D, Webster S, Wegrzyniak B, Wenk G, Wyss-Coray T. Inflammation and Alzheimer’s disease. Neurobiology of aging. 2000;21(3):383–421. - PMC - PubMed
-
- Association A.s. 2014 Alzheimer’s disease facts and figures. Alzheimer’s & Dementia. 2014;10(2):e47–e92. - PubMed
-
- Barba R, Zapatero A, Losa JE, Valdes V, Todoli JA, Di Micco P, Monreal M, Riete I. Body mass index and mortality in patients with acute venous thromboembolism: findings from the RIETE registry. Journal of thrombosis and haemostasis : JTH. 2008;6(4):595–600. - PubMed
-
- Beck JD, Elter JR, Heiss G, Couper D, Mauriello SM, Offenbacher S. Relationship of periodontal disease to carotid artery intima-media wall thickness: the atherosclerosis risk in communities (ARIC) study. Arteriosclerosis, thrombosis, and vascular biology. 2001;21(11):1816–22. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- UL1 TR001445/TR/NCATS NIH HHS/United States
- R01 AG022374/AG/NIA NIH HHS/United States
- R03 DE023139/DE/NIDCR NIH HHS/United States
- R01 AG035137/AG/NIA NIH HHS/United States
- AG035137/AG/NIA NIH HHS/United States
- R21 AG032554/AG/NIA NIH HHS/United States
- R01 AG013616/AG/NIA NIH HHS/United States
- P30 AG008051/AG/NIA NIH HHS/United States
- DE023139-02/DE/NIDCR NIH HHS/United States
- R01 AG012101/AG/NIA NIH HHS/United States
- AG022374/AG/NIA NIH HHS/United States
- AG032554/AG/NIA NIH HHS/United States
- AG13616/AG/NIA NIH HHS/United States
- 8 UL1 TR000038/TR/NCATS NIH HHS/United States
- UL1 TR000038/TR/NCATS NIH HHS/United States
- AG12101/AG/NIA NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources